pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
CYCLOPHOSPHAMIDE
Phase 3 · small molecule · The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT
CYCLOPHOSPHAMIDE for The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT
- Status
- active
- Trials
- 1